Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Ophthalmology. 2015 Oct 31;123(1):129–140. doi: 10.1016/j.ophtha.2015.09.005

Figure 5. Cumulative ranking probabilities for each drug.

Figure 5

The SUCRA value (SUrface under the Cumulative RAnking curve) represents the surface underneath the cumulative ranking curve and is the posterior probabilities for each drug to be among the n-best options (15, 16). The larger the SUCRA value, the higher the ranking probabilities for the drug among the drugs compared. Rankings based on SUCRA values account better for the uncertainly in the estimated treatment effects (15, 16).

SUCRA values normalized to %:

Placebo (0.01), Apraclonidine (30.55), Brimonidine (57.09), Betaxolol (21.62), Carteolol (53.44), Levobunolol (77.96), Timolol (60.39), Levobetaxolol (31.56), Brinzolamide (27.67), Dorzolamide (30.36), Bimatoprost (99.66), Latanoprost (86.56), Travoprost (85.76), Tafluprost (74.79), Unoprostone (12.44)